AT(1) receptor antagonists-beyond blood pressure control: possible place in heart failure treatment.
McMurray
J
J
CRI in Heart Failure, Wolfson Building-Room 363, University of Glasgow, Glasgow G12 8QQ, UK. j.mcmurray@bio.gla.ac.uk
D000368:Aged; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D013777:Tetrazoles / Q000627:therapeutic use*; D020257:Ventricular Remodeling / Q000187:drug effects
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D013777:Tetrazoles; C081643:candesartan